NT5C and neoplasm: Second, while the antitumor efficacy of CDN was demonstrated in a subcutaneous xenograft model, its interaction with the tumor immune microenvironment warrants deeper investigation, ideally using patient-derived xenograft (PDX) models that better recapitulate human tumor biology.